Since 2011 MLN has become a disease of serious concern in the east African countries of Kenya, Tanzania, Uganda and possibly Rwanda. CIMMYT has been working in close collaboration with the Kenya Agricultural Research Institute (KARI), private sector partners and virology experts from the USA to combat the disease through host-controlled resistance. A CIMMYT-KARI MLN Screening Facility was established at Naivasha in September 2013, and a large array of maize germplasm is presently being evaluated against the disease under artificial inoculation. Subsequent to the development of effective protocols, CIMMYT and KARI have been conducting MLN screening trials in Kenya since 2012, to identify promising inbred lines and pre-commercial maize hybrids with resistance to MLN. This is the second update of the information on potential MLN-resistant or moderately resistant inbred lines and pre-commercial hybrids (in CIMMYT genetic backgrounds), following the first update that was shared with public and private sector partners in May 2013.
New and improved maize hybrids, developed by the CIMMYT Global Maize Program, are available for uptake by public and private sector partners, especially those interested in marketing or disseminating hybrid maize seed across Southern Africa and similar agro-ecological zones. Following a rigorous trialing and a stage-gate advancement process CIMMYT advanced a set of new elite maize hybrids in Southern Africa in 2018. Phenotypic data collected in Stage 4 trials for the selected hybrids as well as information about the trial sites are provided in this dataset. These trials were conducted through a network of partners, including NARES and private seed companies, in Southern Africa under various management and environmental conditions.
New and improved maize hybrids, developed by the CIMMYT Global Maize Program, are available for uptake by public and private sector partners, especially those interested in marketing or disseminating hybrid maize seed across Eastern Africa and similar agro-ecological zones. Following a rigorous trialing and a stage-gate advancement process CIMMYT advanced a set of new elite maize hybrids in Eastern Africa in 2018. Phenotypic data collected in Stage 4 trials for the selected hybrids as well as information about the trial sites are provided in this dataset. These trials were conducted through a network of partners, including NARES and private seed companies, in Eastern Africa under various management and environmental conditions. The summary results of the Regional Trials for CIMMYT Maize Hybrids in Eastern Africa for 2017. The trials include: EHYB17-Set I – Early/extra-early maturing elite pre-commercial hybrids regional trials (including external and internal checks); IHYB17-Set I – Intermediate maturing elite pre-commercial hybrids regional trial (including external and internal checks); ILHYB17 – Intermediate-Late maturing elite pre-released and released hybrids regional trials (including external and internal checks); EHYB17-Set II – Early maturing elite pre-commercial hybrids regional trials; ILHYB17 Set II – Intermediate/late maturing elite pre-commercial hybrids regional trials.
New and improved maize hybrids, developed by the CIMMYT Global Maize Program, are available for uptake by public and private sector partners, especially those interested in marketing or disseminating hybrid maize seed across eastern and southern Africa and similar agro-ecological zones. Following a rigorous trialing and a stage-gate advancement process CIMMYT advanced new elite maize hybrids in eastern and southern Africa in 2019. Phenotypic data collected in trials for the selected hybrids as well as information about the trial sites are provided in this dataset. These trials were conducted through a network of partners, including NARES and private seed companies, in eastern and southern Africa under various management and environmental conditions. The summary results of the Regional Trials for CIMMYT Maize Hybrids in Eastern Africa for 2018 specific to different product profiles. The trials include: IHYB18 – Intermediate maturing elite pre-commercial hybrids regional trial: Product profile 1A (Eastern Africa) - Basic traits (Intermediate maturing, white, high yielding, drought tolerant, NUE, and resistant to GLS, TLB, Ear rots, and MSV); Nice to have/emerging traits (MLN, Striga, FAW). MLN 3WAY HYB18 - Intermediate maturing elite pre-commercial MLN 3way hybrids regional trial: Product profile 1B (Eastern Africa): Basic traits (Intermediate-maturing, white, high-yielding, drought tolerant, NUE, resistant to MLN, MSV, TLB); Nice to have/ emerging traits (FAW, Striga). ILHYB18 – Intermediate-Late maturing elite pre-released and released hybrids regional trials: Product profile 2 (Eastern Africa) - Basic traits (Late-maturing, white, high-yielding, Drought tolerance, NUE, and resistant to GLS, TLB, MSV Ear Rots, and rust); Nice to have/ Emerging traits (FAW, MLN, Striga). EHYB18 – Early/extra-early maturing elite pre-commercial hybrids regional trials: Product profile 3 (Eastern Africa) - Basic Traits (Early-maturing, white, high-yielding, Drought tolerant, and resistant to MSV and MLN, NUE); Nice to have traits (Heat tolerant, TLB, Rust, Striga). Pro-A HYBSI7; Pro-A HYBSI8- Intermediate maturing elite pre-commercial Provitamin A hybrids regional trial: Product profile 3 (Southern Africa)- Basic traits (Nutritious maize, early-late maturity, orange and/ white, high yield, high pvA, high Zn, high Lysine and tryp, tolerance to drought, low N, heat and low soil pH stresses and tolerance to MSV, GLS, TLB and cob rot);Nice to have traits (MLN, FAW, Downy mildew, aflatoxin, rust, organoleptic test, bioavailability, suitability for value-added products).
